<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-284 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-284</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-284</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-25436023</p>
                <p><strong>Paper Title:</strong> Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data</p>
                <p><strong>Paper Abstract:</strong> Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The probing of the NSCLC kinome has identified numerous nonoverlapping driver genomic events, including epidermal growth factor receptor (EGFR) gene mutations. This review provides a synopsis of preclinical and clinical data on EGFR mutated NSCLC and EGFR tyrosine kinase inhibitors (TKIs). Classic somatic EGFR kinase domain mutations (such as L858R and exon 19 deletions) make tumors addicted to their signaling cascades and generate a therapeutic window for the use of ATP-mimetic EGFR TKIs. The latter inhibit these kinases and their downstream effectors, and induce apoptosis in preclinical models. The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. The benefits associated with these EGFR TKIs are limited by the mechanisms of tumor resistance, such as the gatekeeper EGFR-T790M mutation, and bypass activation of signaling cascades. Ongoing preclinical efforts for treating resistance have started to translate into patient care (including clinical trials of the covalent EGFR-T790M TKIs AZD9291 and CO-1686) and hold promise to further boost the median survival of patients with EGFR mutated NSCLC.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e284.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e284.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_prevalence_by_ethnicity</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (EGFR) mutation prevalence in NSCLC by ethnicity (East Asian vs European/African)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Review-reported overall prevalence estimates for EGFR-sensitizing mutations in non-small-cell lung cancer (NSCLC), with explicit contrasts between East Asian and European/African populations and a separate prevalence for never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>East Asian; European or African</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>East Asia; Europe/Africa (not a single study; aggregated/review-level statement)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>East Asians: ~35% of NSCLCs overall; European or African ethnicities: ~15% of NSCLCs overall; Never-smokers: ~50% of NSCLCs overall</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Among EGFR-mutant tumors overall: exon 19 deletions ~45% of EGFR mutations; L858R (exon 21) ~40%; exon 20 in-frame insertions 5-10%; exon 18 G719 point mutations ~3%; exon 21 L861Q ~2%; rare exon 19 insertions <1%. (These are overall distributions among EGFR-mutant cases, not stratified by ethnicity in this paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>East Asian: ~35% EGFR-mutant NSCLC; European/African: ~15% EGFR-mutant NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>EGFR mutations are much more frequent in never-smokers; the review reports ~50% prevalence in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>EGFR mutations are reported as more frequent in women.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>The paper states that the etiology underlying EGFR mutations is elusive; it notes rare inherited germline EGFR mutations (e.g., germline T790M and V843I) can be loci associated with familial clustering, where tumors develop when a somatic classic EGFR mutation occurs in the background of an inherited allele. GWAS have not revealed a unifying inherited genetic basis for EGFR-mutant lung cancer in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td>No specific environmental explanations for ethnic differences are proposed in this review; the authors state that environmental and inherited risk factors for lung cancer in never-smokers are poorly understood.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>The paper links smoking status to mutation frequency (EGFR mutations are enriched in never-smokers) but does not propose other lifestyle factors (diet, cooking practices, etc.) as explanations for ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No other concrete explanations (e.g., detection bias or healthcare access) are proposed; the review emphasizes that the etiology remains elusive and highlights familial germline mutations as a rare contributor.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Predominantly adenocarcinoma / nonsquamous NSCLC (EGFR mutations are more frequent in adenocarcinomas)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Not stratified by ethnicity in the prevalence statement; more generally, classic EGFR sensitizing mutations strongly predict high response rates and longer progression-free survival to EGFR TKIs (gefitinib, erlotinib, afatinib) across trials.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data', 'publication_date_yy_mm': '2014-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e284.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e284.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Germline_EGFR_predisposition</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inherited germline EGFR mutations (examples: T790M, V843I) and familial clustering</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review mentions rare germline EGFR variants that can predispose to familial clustering of EGFR-mutant NSCLC, with tumors arising when somatic sensitizing EGFR mutations co-occur with the inherited allele.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>not specified (described as rare familial cases across populations)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Germline examples cited: T790M, V843I (germline); somatic co-occurrence with classic sensitizing mutations (exon 19 deletions, L858R) leads to tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Not specified for germline cases in the review; germline-associated tumors are highlighted as a distinct familial phenomenon.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>Yes â€” the review proposes that rare inherited germline EGFR mutations can increase familial clustering risk; tumor development may require somatic acquisition of a classic sensitizing EGFR mutation in the presence of the inherited allele.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The review notes overall that the broader causes of ethnic differences are unknown and that GWAS have been relatively unrevealing for a unifying basis in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Not specifically limited by histology in the germline discussion, but context is NSCLC/adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Not specified for germline-driven tumors in this review; implication is that tumors harboring classic sensitizing somatic mutations respond to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data', 'publication_date_yy_mm': '2014-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>